Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
Clin Cancer Res. 2021 Sep 14:clincanres.1562.2021. doi: 10.1158/1078-0432.CCR-21-1562. Online ahead of print.ABSTRACTPURPOSE: Serum Thymidine Kinase 1 (sTK1) activity is associated with poor prognosis in metastatic breast cancer (MBC). We assessed the prognostic effect of sTK1 in patients with hormone receptor-positive MBC treated on a prospective randomized trial of anastrozole (A) vs. A plus fulvestrant (A+F).EXPERIMENTAL DESIGN: sTK1 was assessed in 1,726 serums [baseline (BL), cycles 2, 3, 4, and 7] using the DiviTum® assay. A pre-specified cutoff of {greater than or equal to}200 Du/L was considered high. Progressi...
Source: Clinical Breast Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research

Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
Clin Cancer Res. 2021 Sep 14:clincanres.1562.2021. doi: 10.1158/1078-0432.CCR-21-1562. Online ahead of print.ABSTRACTPURPOSE: Serum Thymidine Kinase 1 (sTK1) activity is associated with poor prognosis in metastatic breast cancer (MBC). We assessed the prognostic effect of sTK1 in patients with hormone receptor-positive MBC treated on a prospective randomized trial of anastrozole (A) vs. A plus fulvestrant (A+F).EXPERIMENTAL DESIGN: sTK1 was assessed in 1,726 serums [baseline (BL), cycles 2, 3, 4, and 7] using the DiviTum® assay. A pre-specified cutoff of {greater than or equal to}200 Du/L was considered high. Progressi...
Source: Clinical Breast Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research

Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
Clin Cancer Res. 2021 Sep 14:clincanres.1562.2021. doi: 10.1158/1078-0432.CCR-21-1562. Online ahead of print.ABSTRACTPURPOSE: Serum Thymidine Kinase 1 (sTK1) activity is associated with poor prognosis in metastatic breast cancer (MBC). We assessed the prognostic effect of sTK1 in patients with hormone receptor-positive MBC treated on a prospective randomized trial of anastrozole (A) vs. A plus fulvestrant (A+F).EXPERIMENTAL DESIGN: sTK1 was assessed in 1,726 serums [baseline (BL), cycles 2, 3, 4, and 7] using the DiviTum® assay. A pre-specified cutoff of {greater than or equal to}200 Du/L was considered high. Progressi...
Source: Clinical Breast Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research

Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
Clin Cancer Res. 2021 Sep 14:clincanres.1562.2021. doi: 10.1158/1078-0432.CCR-21-1562. Online ahead of print.ABSTRACTPURPOSE: Serum Thymidine Kinase 1 (sTK1) activity is associated with poor prognosis in metastatic breast cancer (MBC). We assessed the prognostic effect of sTK1 in patients with hormone receptor-positive MBC treated on a prospective randomized trial of anastrozole (A) vs. A plus fulvestrant (A+F).EXPERIMENTAL DESIGN: sTK1 was assessed in 1,726 serums [baseline (BL), cycles 2, 3, 4, and 7] using the DiviTum® assay. A pre-specified cutoff of {greater than or equal to}200 Du/L was considered high. Progressi...
Source: Clinical Breast Cancer - September 15, 2021 Category: Cancer & Oncology Authors: Costanza Paoletti William E Barlow Erin F Cobain Mattias Bergqvist Rita S Mehta Julie R Gralow Gabriel N Hortobagyi Kathy S Albain Lajos Pusztai Priyanka Sharma Andrew K Godwin Alastair M Thompson Daniel F Hayes James M Rae Source Type: research

A Phase 1 Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel using a novel Randomized Continual Reassessment Method for Dose Escalation
Clin Cancer Res. 2021 Sep 13:clincanres.4185.2020. doi: 10.1158/1078-0432.CCR-20-4185. Online ahead of print.ABSTRACTPURPOSE: MPS1 kinase inhibitor, BAY 1217389 (BAY) synergizes with paclitaxel. This phase 1 study assessed the combination of BAY with paclitaxel using a novel randomized continuous reassessment method (rCRM) to improve dose determination.EXPERIMENTAL DESIGN: Patients with solid tumors were randomized to receive oral BAY (BID 2‑days‑on/5‑days‑off) with weekly paclitaxel (90 mg/m2) or paclitaxel monotherapy in cycle 1. Dose escalation was guided by CRM modeling. Primary objectives were to assess safety...
Source: Clinical Breast Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Florence Atrafi Oliver Boix Vivek Subbiah Jennifer R Diamond Sant P Chawla Anthony W Tolcher Patricia M LoRusso Joseph Paul Eder Martin Gutierrez Kumar Sankhala Prabhu Rajagopalan Isabelle Genvresse Simon Langer Ron Hj Mathijssen Jaap Verweij Ingmar Bruns Source Type: research

Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer
CONCLUSIONS: Combination of olaparib and capivasertib is associated to no serious adverse events and demonstrates durable activity in ovarian, endometrial and breast cancers, with promising responses in endometrial cancer. Importantly, tumor samples acquired pre- and on-therapy can help predict patient benefit.PMID:34518313 | DOI:10.1158/1078-0432.CCR-21-1656 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Shannon N Westin Marilyne Labrie Jennifer K Litton Aurora Blucher Yong Fang Christopher P Vellano Joseph R Marszalek Ningping Feng Xiaoyan Ma Allison Creason Bryan Fellman Ying Yuan Sanghoon Lee TaeBeom Kim Jinsong Liu Anca Chelariu-Raicu Tsun Hsuan Chen Source Type: research

miR-522 regulates cell proliferation, migration, invasion capacities and acts as a potential biomarker to predict prognosis in triple-negative breast cancer
This study was designed to explore the cell functions and prognostic significance of miR-522 in triple-negative breast cancer. The expression levels of miR-522 in triple-negative breast cancer tissues and cell lines were detected by quantitative real-time PCR analysis. Kaplan-Meier curve and Cox regression analysis were used to investigate the relationship between miR-522 expression and prognosis of patients, and to evaluate the possibility of miR-522 as a potential indicator for predicting the prognosis of triple-negative breast cancer. The CCK-8 and transwell assays were used to assess cell proliferation, migration, and ...
Source: Clinical Breast Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Wei Wang Wei Zhang Jianhua Wu Zhuchao Zhou Jinglin Ma Source Type: research

Quality of Life and Hope of Women in China Receiving Chemotherapy for Breast Cancer
Clin Nurs Res. 2021 Sep 14:10547738211046737. doi: 10.1177/10547738211046737. Online ahead of print.ABSTRACTWe explore the association of hope and quality of life in breast cancer chemotherapy women. Their quality of life is related to treatment effects and disease outcomes. This cross-sectional study was conducted in City, China, in 2017. In a convenience sampling, 450 women who underwent breast cancer chemotherapy were selected from two hospitals. Descriptive statistics, single-factor analysis, Spearman correlation, linear regression, and structural equation modeling were used to analyze data. The mean quality of life sc...
Source: Clinical Breast Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Yuan Li Zijun Zhou Na Ni Jiaxin Li Ze Luan Xin Peng Source Type: research

The Impact of COVID-19 on Patients With Cancer: A National Study of Patient Experiences
The objective of this study was to assess patients' perspectives regarding the impact of COVID-19 on their experiences, including their cancer care, emotional and mental health, and social determinants of health, and to evaluate whether these outcomes differed by cancer stage.MATERIALS AND METHODS: We conducted a survey among adults with cancer across the United States from April 1, 2020 to August 26, 2020 using virtual snowball sampling strategy in collaboration with professional organizations, cancer care providers, and patient advocacy groups. We analyzed data using descriptive statistics, χ2 and t tests.RESULTS: Th...
Source: Clinical Breast Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Gladys M Rodriguez Jacqueline M Ferguson Allison Kurian Melissa Bondy Manali I Patel Source Type: research

HER2-Low Breast Cancers
CONCLUSIONS: The promising efficacy of novel HER2-targeted therapy in advanced HER2-low breast cancers has raised the possibility for changing the clinical interpretation of HER2 status in breast cancer to include a HER2-low category; however, the definition of HER2-low breast cancer, the corresponding reliable and accurate quantitative HER2 testing methodology, and the biology of HER2-low breast cancer remain poorly defined.PMID:34519765 | DOI:10.1093/ajcp/aqab117 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Huina Zhang Hani Katerji Bradley M Turner David G Hicks Source Type: research

Breast cancer derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment
J Clin Invest. 2021 Sep 14:145296. doi: 10.1172/JCI145296. Online ahead of print.ABSTRACTTumor-infiltrating myeloid cells contribute to the development of the immunosuppressive tumor microenvironment. Myeloid cell expression of arginase 1 (Arg-1) promotes a protumor phenotype by inhibiting T cell function and depleting extracellular L-arginine, but the mechanism underlying this expression, especially in breast cancer, is poorly understood. In breast cancer clinical samples and in our mouse models, we identified tumor derived GM-CSF as the primary regulator of myeloid cell Arg-1 expression and local immune suppression throu...
Source: Clinical Breast Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Xinming Su Yalin Xu Gregory C Fox Jingyu Xiang Kristin A Kwakwa Jennifer L Davis Jad I Belle Wen-Chih Lee Wing H Wong Francesca Fontana Leonel Hernandez-Aya Takayuki Kobayashi Helen M Tomasson Junyi Su Suzanne J Bakewell Sheila A Stewart Christopher Egbul Source Type: research

A Phase 1 Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel using a novel Randomized Continual Reassessment Method for Dose Escalation
Clin Cancer Res. 2021 Sep 13:clincanres.4185.2020. doi: 10.1158/1078-0432.CCR-20-4185. Online ahead of print.ABSTRACTPURPOSE: MPS1 kinase inhibitor, BAY 1217389 (BAY) synergizes with paclitaxel. This phase 1 study assessed the combination of BAY with paclitaxel using a novel randomized continuous reassessment method (rCRM) to improve dose determination.EXPERIMENTAL DESIGN: Patients with solid tumors were randomized to receive oral BAY (BID 2‑days‑on/5‑days‑off) with weekly paclitaxel (90 mg/m2) or paclitaxel monotherapy in cycle 1. Dose escalation was guided by CRM modeling. Primary objectives were to assess safety...
Source: Clinical Breast Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Florence Atrafi Oliver Boix Vivek Subbiah Jennifer R Diamond Sant P Chawla Anthony W Tolcher Patricia M LoRusso Joseph Paul Eder Martin Gutierrez Kumar Sankhala Prabhu Rajagopalan Isabelle Genvresse Simon Langer Ron Hj Mathijssen Jaap Verweij Ingmar Bruns Source Type: research

Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer
CONCLUSIONS: Combination of olaparib and capivasertib is associated to no serious adverse events and demonstrates durable activity in ovarian, endometrial and breast cancers, with promising responses in endometrial cancer. Importantly, tumor samples acquired pre- and on-therapy can help predict patient benefit.PMID:34518313 | DOI:10.1158/1078-0432.CCR-21-1656 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Shannon N Westin Marilyne Labrie Jennifer K Litton Aurora Blucher Yong Fang Christopher P Vellano Joseph R Marszalek Ningping Feng Xiaoyan Ma Allison Creason Bryan Fellman Ying Yuan Sanghoon Lee TaeBeom Kim Jinsong Liu Anca Chelariu-Raicu Tsun Hsuan Chen Source Type: research

miR-522 regulates cell proliferation, migration, invasion capacities and acts as a potential biomarker to predict prognosis in triple-negative breast cancer
This study was designed to explore the cell functions and prognostic significance of miR-522 in triple-negative breast cancer. The expression levels of miR-522 in triple-negative breast cancer tissues and cell lines were detected by quantitative real-time PCR analysis. Kaplan-Meier curve and Cox regression analysis were used to investigate the relationship between miR-522 expression and prognosis of patients, and to evaluate the possibility of miR-522 as a potential indicator for predicting the prognosis of triple-negative breast cancer. The CCK-8 and transwell assays were used to assess cell proliferation, migration, and ...
Source: Clinical Breast Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Wei Wang Wei Zhang Jianhua Wu Zhuchao Zhou Jinglin Ma Source Type: research

Using Computed Tomography Lymphography for Mapping of Sentinel Lymph Nodes in Patients with Breast Cancer
CONCLUSION: CTLG has a high identification rate in sentinel lymph nodes, and it is considered a convenient and useful examination method because a lot of information, such as the number and position of sentinel lymph nodes, can be obtained.PMID:34513207 | PMC:PMC8422530 | DOI:10.25259/JCIS_33_2021 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 13, 2021 Category: Cancer & Oncology Authors: Arimichi Kamata Taku Miyamae Masaki Koizumi Harigane Kohei Hideki Sarukawa Hiroshi Nemoto Koji Hino Source Type: research

Ultrasound Imaging Morphology is Associated with Biological Behavior in Invasive Ductal Carcinoma of the Breast
CONCLUSION: In this study of over 450 IDCs, significant statistical associations between tumor grade and receptor status with US imaging morphology were observed and could serve as a surrogate imaging marker for the biological behavior of the tumor.PMID:34513212 | PMC:PMC8422408 | DOI:10.25259/JCIS_60_2021 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 13, 2021 Category: Cancer & Oncology Authors: Gopal R Vijayaraghavan Matthew Kona Abiramy Maheswaran Dina H Kandil Madhavi K Toke Srinivasan Vedantham Source Type: research

TRIM25: A central factor in breast cancer
World J Clin Oncol. 2021 Aug 24;12(8):646-655. doi: 10.5306/wjco.v12.i8.646.ABSTRACTTRIM25 is emerging as a central factor in breast cancer due to its regulation and function. In particular, it has been shown that: (1) Estrogens modulate TRIM25 gene expression; (2) TRIM25 has activity as an E3-ligase enzyme for ubiquitin; and (3) TRIM25 is also an E3 ligase for interferon-stimulated gene 15 protein in the ISGylation system. Consequently, the proteome of mammary tissue is affected by TRIM25-associated pathways, involved in tumor development and metastasis. Here, we discuss the findings on the mechanisms involved in regulati...
Source: Clinical Breast Cancer - September 13, 2021 Category: Cancer & Oncology Authors: Angeles C Tecalco-Cruz Mar ía Jazmin Abraham-Juárez Helena Solleiro-Villavicencio Josu é Orlando Ramírez-Jarquín Source Type: research

PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report
CONCLUSION: The detection of PIK3CA mutation in TNBC after neoadjuvant treatment might be associated with early relapse or rapid disease progression.PMID:34513603 | PMC:PMC8394163 | DOI:10.5306/wjco.v12.i8.702 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 13, 2021 Category: Cancer & Oncology Authors: Guillermo Arturo Valencia Patricia Rioja Zaida Morante Jhajaira M Araujo Heberth Daniel Vallejos Henry Guerra Henry L Gomez Source Type: research

Trends in Cardiovascular mortality of cancer patients in the US over two decades 1999-2019
CONCLUSIONS: Our findings emphasize the role multidisciplinary management of cancer patients. Widespread adoption of cardio oncology services have the potential to impact the inherent risk of increased CV mortality in both cancer patients and survivors.PMID:34514707 | DOI:10.1111/ijcp.14841 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 13, 2021 Category: Cancer & Oncology Authors: Ofer Kobo Sophia Khattak Juan Lopez-Mattei Harriette G C Van Spall Michelle Graham Richard K Cheng Mohammed Osman Louise Sun Waqas Ullah David L Fischman Ariel Roguin Mohamed O Mohamed Mamas A Mamas Source Type: research

Can belly dance and mat Pilates be effective for range of motion, self-esteem, and depressive symptoms of breast cancer women?
CONCLUSION: Belly dance and the Mat Pilates can bring positive results in the range of movement of women undergoing adjuvant treatment of breast cancer, with the Pilates method being the one that most contributed to improvements in this variable.PMID:34517217 | DOI:10.1016/j.ctcp.2021.101483 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 13, 2021 Category: Cancer & Oncology Authors: Bruna Leite Tatiana de Bem Fretta Leonessa Boing Adriana Coutinho de Azevedo Guimar ães Source Type: research

Accuracy of contrast-enhanced spectral mammography compared with MRI for invasive breast cancers: Prospective study in population of predominantly underrepresented minorities
CONCLUSIONS: CESM is an effective imaging modality for evaluating the extent of disease in newly diagnosed invasive breast cancers and a good alternative to MRI in a multiethnic population.PMID:34509973 | DOI:10.1016/j.clinimag.2021.08.015 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 12, 2021 Category: Cancer & Oncology Authors: Sandy C Lee Linda Hovanessian-Larsen Daniel Stahl Steven Cen Xiaomeng Lei Bhushan Desai Mary Yamashita Source Type: research

Lysophosphatidic acid receptor 6 regulated by miR-27a-3p attenuates tumor proliferation in breast cancer
CONCLUSION: LPAR6 acts as a tumor suppressor in breast cancer and is positively regulated by miR-27a-3p.PMID:34510318 | DOI:10.1007/s12094-021-02704-8 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 12, 2021 Category: Cancer & Oncology Authors: J Lei S Guo K Li J Tian B Zong T Ai Y Peng Y Zhang S Liu Source Type: research

Accuracy of contrast-enhanced spectral mammography compared with MRI for invasive breast cancers: Prospective study in population of predominantly underrepresented minorities
CONCLUSIONS: CESM is an effective imaging modality for evaluating the extent of disease in newly diagnosed invasive breast cancers and a good alternative to MRI in a multiethnic population.PMID:34509973 | DOI:10.1016/j.clinimag.2021.08.015 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 12, 2021 Category: Cancer & Oncology Authors: Sandy C Lee Linda Hovanessian-Larsen Daniel Stahl Steven Cen Xiaomeng Lei Bhushan Desai Mary Yamashita Source Type: research

Lysophosphatidic acid receptor 6 regulated by miR-27a-3p attenuates tumor proliferation in breast cancer
CONCLUSION: LPAR6 acts as a tumor suppressor in breast cancer and is positively regulated by miR-27a-3p.PMID:34510318 | DOI:10.1007/s12094-021-02704-8 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 12, 2021 Category: Cancer & Oncology Authors: J Lei S Guo K Li J Tian B Zong T Ai Y Peng Y Zhang S Liu Source Type: research

Left Ventricular Diastolic Function Following Anthracycline-Based Chemotherapy in Patients with Breast Cancer without Previous Cardiac Disease-A Meta-Analysis
CONCLUSIONS: ANT had a modest early impact on E/A ratio, without changing EDT, e', or E/e' in patients with breast cancer without cardiac disease. Randomised studies on larger populations, using new parameters are required to define the role of diastolic dysfunction in the early diagnosis of ANT-induced cardiotoxicity.PMID:34501337 | PMC:PMC8432074 | DOI:10.3390/jcm10173890 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Raluca I Mincu Lena F Lampe Amir A Mahabadi Rainer Kimmig Tienush Rassaf Matthias Totzeck Source Type: research

Pili Torti: A Feature of Numerous Congenital and Acquired Conditions
J Clin Med. 2021 Aug 30;10(17):3901. doi: 10.3390/jcm10173901.ABSTRACTPili torti is a rare condition characterized by the presence of the hair shaft, which is flattened at irregular intervals and twisted 180° along its long axis. It is a form of hair shaft disorder with increased fragility. The condition is classified into inherited and acquired. Inherited forms may be either isolated or associated with numerous genetic diseases or syndromes (e.g., Menkes disease, Björnstad syndrome, Netherton syndrome, and Bazex-Dupré-Christol syndrome). Moreover, pili torti may be a feature of various ectodermal dysplasia...
Source: Clinical Breast Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Aleksandra Hoffmann Anna Wa śkiel-Burnat Jakub Żółkiewicz Leszek Blicharz Adriana Rakowska Mohamad Goldust Ma łgorzata Olszewska Lidia Rudnicka Source Type: research

Making a convenient, low-cost phantom with a previously unreported material for practicing ultrasound-guided procedures
J Clin Ultrasound. 2021 Sep 10. doi: 10.1002/jcu.23065. Online ahead of print.ABSTRACTUltrasound-guided procedures require excellent hand-eye coordination and practice. Trainees should gain this important skill with a phantom prior to performing procedures on patients. Currently available phantoms each have their own unique limitations. We propose an easily made, inexpensive, tissue-like phantom using a previously unreported material. The sonographic appearance of the phantom, with and without a 14-gauge needle, is compared with breast tissue, gelatin phantoms, and commercial phantoms. Target lesions can be produced using ...
Source: Clinical Breast Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Xiaoqin Wang Christine Joyce John Kuipers Source Type: research

Reply to M. Tanaka et al
J Clin Oncol. 2021 Sep 10:JCO2101967. doi: 10.1200/JCO.21.01967. Online ahead of print.NO ABSTRACTPMID:34506210 | DOI:10.1200/JCO.21.01967 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Sara M Tolaney Ann H Partridge Eric P Winer Ian E Krop Source Type: research

Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Escalation or De-Escalation?
J Clin Oncol. 2021 Sep 10:JCO2101716. doi: 10.1200/JCO.21.01716. Online ahead of print.NO ABSTRACTPMID:34506214 | DOI:10.1200/JCO.21.01716 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Maho Tanaka Akihiko Shimomura Hiroyuki Terakado Chikako Shimizu Source Type: research

Peripheral blood immune markers in breast cancer: Differences in regulatory T cell abundance are related to clinical parameters
CONCLUSION: The results of this exploratory study contribute to the elucidation of the systemic immune response in breast cancer indicating a potential use of peripheral immune cell counts and Tregs to distinguish patients from healthy controls and as potential diagnostic and prognostic biomarkers to be investigated in future studies.PMID:34506945 | DOI:10.1016/j.clim.2021.108847 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Nanna J ørgensen Anne-Vibeke L ænkholm Susanne Gj ørup Sækmose Lone Bak Hansen Thomas Vauvert F Hviid Source Type: research

Outcomes of screening mammography performed prior to fertility treatment in women ages 40-49
CONCLUSION: Screening mammography in women 40-49 performed prior to initiation of ART may identify asymptomatic breast malignancy. In accordance with ACR and SBI guidelines to screen women of this age group, women of this age group should undergo screening mammography prior to ART.PMID:34507268 | DOI:10.1016/j.clinimag.2021.08.028 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Heather I Greenwood Elissa R Price Amie Y Lee Tatiana Kelil Camille Jones Mai Le Eleni G Jaswa Source Type: research

Left Ventricular Diastolic Function Following Anthracycline-Based Chemotherapy in Patients with Breast Cancer without Previous Cardiac Disease-A Meta-Analysis
CONCLUSIONS: ANT had a modest early impact on E/A ratio, without changing EDT, e', or E/e' in patients with breast cancer without cardiac disease. Randomised studies on larger populations, using new parameters are required to define the role of diastolic dysfunction in the early diagnosis of ANT-induced cardiotoxicity.PMID:34501337 | DOI:10.3390/jcm10173890 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Raluca I Mincu Lena F Lampe Amir A Mahabadi Rainer Kimmig Tienush Rassaf Matthias Totzeck Source Type: research

Pili Torti: A Feature of Numerous Congenital and Acquired Conditions
J Clin Med. 2021 Aug 30;10(17):3901. doi: 10.3390/jcm10173901.ABSTRACTPili torti is a rare condition characterized by the presence of the hair shaft, which is flattened at irregular intervals and twisted 180° along its long axis. It is a form of hair shaft disorder with increased fragility. The condition is classified into inherited and acquired. Inherited forms may be either isolated or associated with numerous genetic diseases or syndromes (e.g., Menkes disease, Björnstad syndrome, Netherton syndrome, and Bazex-Dupré-Christol syndrome). Moreover, pili torti may be a feature of various ectodermal dysplasia...
Source: Clinical Breast Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Aleksandra Hoffmann Anna Wa śkiel-Burnat Jakub Żółkiewicz Leszek Blicharz Adriana Rakowska Mohamad Goldust Ma łgorzata Olszewska Lidia Rudnicka Source Type: research

Making a convenient, low-cost phantom with a previously unreported material for practicing ultrasound-guided procedures
J Clin Ultrasound. 2021 Sep 10. doi: 10.1002/jcu.23065. Online ahead of print.ABSTRACTUltrasound-guided procedures require excellent hand-eye coordination and practice. Trainees should gain this important skill with a phantom prior to performing procedures on patients. Currently available phantoms each have their own unique limitations. We propose an easily made, inexpensive, tissue-like phantom using a previously unreported material. The sonographic appearance of the phantom, with and without a 14-gauge needle, is compared with breast tissue, gelatin phantoms, and commercial phantoms. Target lesions can be produced using ...
Source: Clinical Breast Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Xiaoqin Wang Christine Joyce John Kuipers Source Type: research

Reply to M. Tanaka et al
J Clin Oncol. 2021 Sep 10:JCO2101967. doi: 10.1200/JCO.21.01967. Online ahead of print.NO ABSTRACTPMID:34506210 | DOI:10.1200/JCO.21.01967 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Sara M Tolaney Ann H Partridge Eric P Winer Ian E Krop Source Type: research

Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Escalation or De-Escalation?
J Clin Oncol. 2021 Sep 10:JCO2101716. doi: 10.1200/JCO.21.01716. Online ahead of print.NO ABSTRACTPMID:34506214 | DOI:10.1200/JCO.21.01716 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Maho Tanaka Akihiko Shimomura Hiroyuki Terakado Chikako Shimizu Source Type: research

Peripheral blood immune markers in breast cancer: Differences in regulatory T cell abundance are related to clinical parameters
CONCLUSION: The results of this exploratory study contribute to the elucidation of the systemic immune response in breast cancer indicating a potential use of peripheral immune cell counts and Tregs to distinguish patients from healthy controls and as potential diagnostic and prognostic biomarkers to be investigated in future studies.PMID:34506945 | DOI:10.1016/j.clim.2021.108847 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Nanna J ørgensen Anne-Vibeke L ænkholm Susanne Gj ørup Sækmose Lone Bak Hansen Thomas Vauvert F Hviid Source Type: research

Outcomes of screening mammography performed prior to fertility treatment in women ages 40-49
CONCLUSION: Screening mammography in women 40-49 performed prior to initiation of ART may identify asymptomatic breast malignancy. In accordance with ACR and SBI guidelines to screen women of this age group, women of this age group should undergo screening mammography prior to ART.PMID:34507268 | DOI:10.1016/j.clinimag.2021.08.028 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 10, 2021 Category: Cancer & Oncology Authors: Heather I Greenwood Elissa R Price Amie Y Lee Tatiana Kelil Camille Jones Mai Le Eleni G Jaswa Source Type: research

A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases
CONCLUSION: TAS-115 appears to demonstrate anti-tumor activity and acceptable tolerability in CRPC patients with bone metastases.PMID:34493431 | DOI:10.1016/j.clgc.2021.07.013 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 8, 2021 Category: Cancer & Oncology Authors: Nobuaki Matsubara Hirotsugu Uemura Satoshi Nagamori Hiroyoshi Suzuki Hiroji Uemura Go Kimura Source Type: research

The use of neoadjuvant therapy to further personalize breast cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):569-572.NO ABSTRACTPMID:34495020 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 8, 2021 Category: Cancer & Oncology Authors: Laura J Esserman Source Type: research

Epithelial-mesenchymal transition (EMT) in vulvar cancer with and without inguinal lymph node involvement
CONCLUSION: The present study shows no differences in the expression of EMT markers between node positive and node negative vulvar cancers. The evaluation of immunostaining within the micro-anatomical context indicates that an EMT-phenotype is restricted to the tumor cells at the front of invasion. Paired analyses of vulvar carcinomas and their lymph node deposits suggest mesenchymal-epithelial transition (MET) in the metastatic deposits. Immunohistochemical staining results may suggest that EMT is more prevalent in vulvar cancer with aberrant p53 staining.PMID:34495397 | DOI:10.1007/s00432-021-03715-2 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 8, 2021 Category: Cancer & Oncology Authors: Christine E Brambs Lars-Christian Horn Meinhard Mende Michael H öckel Christine Eckey Gesine Grit Ruth Hiller Anne Kathrin H öhn Source Type: research

Psoralidin exerts anti-tumor, anti-angiogenic, and immunostimulatory activities in 4T1 tumor-bearing balb/c mice
CONCLUSIONS: Psoralidin shows the anti-cancer potential in an animal model of breast cancer; however, further studies are recommended to elucidate its mechanisms of action.PMID:34496167 | DOI:10.1515/hmbci-2021-0028 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 8, 2021 Category: Cancer & Oncology Authors: Davar Amani Elham Shakiba Ehsan Motaghi Hiva Alipanah Mahshad Jalalpourroodsari Mohsen Rashidi Source Type: research

A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases
CONCLUSION: TAS-115 appears to demonstrate anti-tumor activity and acceptable tolerability in CRPC patients with bone metastases.PMID:34493431 | DOI:10.1016/j.clgc.2021.07.013 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 8, 2021 Category: Cancer & Oncology Authors: Nobuaki Matsubara Hirotsugu Uemura Satoshi Nagamori Hiroyoshi Suzuki Hiroji Uemura Go Kimura Source Type: research

The use of neoadjuvant therapy to further personalize breast cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):569-572.NO ABSTRACTPMID:34495020 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 8, 2021 Category: Cancer & Oncology Authors: Laura J Esserman Source Type: research

Epithelial-mesenchymal transition (EMT) in vulvar cancer with and without inguinal lymph node involvement
CONCLUSION: The present study shows no differences in the expression of EMT markers between node positive and node negative vulvar cancers. The evaluation of immunostaining within the micro-anatomical context indicates that an EMT-phenotype is restricted to the tumor cells at the front of invasion. Paired analyses of vulvar carcinomas and their lymph node deposits suggest mesenchymal-epithelial transition (MET) in the metastatic deposits. Immunohistochemical staining results may suggest that EMT is more prevalent in vulvar cancer with aberrant p53 staining.PMID:34495397 | DOI:10.1007/s00432-021-03715-2 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 8, 2021 Category: Cancer & Oncology Authors: Christine E Brambs Lars-Christian Horn Meinhard Mende Michael H öckel Christine Eckey Gesine Grit Ruth Hiller Anne Kathrin H öhn Source Type: research

Psoralidin exerts anti-tumor, anti-angiogenic, and immunostimulatory activities in 4T1 tumor-bearing balb/c mice
CONCLUSIONS: Psoralidin shows the anti-cancer potential in an animal model of breast cancer; however, further studies are recommended to elucidate its mechanisms of action.PMID:34496167 | DOI:10.1515/hmbci-2021-0028 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 8, 2021 Category: Cancer & Oncology Authors: Davar Amani Elham Shakiba Ehsan Motaghi Hiva Alipanah Mahshad Jalalpourroodsari Mohsen Rashidi Source Type: research

A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases
CONCLUSION: TAS-115 appears to demonstrate anti-tumor activity and acceptable tolerability in CRPC patients with bone metastases.PMID:34493431 | DOI:10.1016/j.clgc.2021.07.013 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 8, 2021 Category: Cancer & Oncology Authors: Nobuaki Matsubara Hirotsugu Uemura Satoshi Nagamori Hiroyoshi Suzuki Hiroji Uemura Go Kimura Source Type: research

The use of neoadjuvant therapy to further personalize breast cancer treatment
Clin Adv Hematol Oncol. 2021 Sep;19(9):569-572.NO ABSTRACTPMID:34495020 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 8, 2021 Category: Cancer & Oncology Authors: Laura J Esserman Source Type: research

Epithelial-mesenchymal transition (EMT) in vulvar cancer with and without inguinal lymph node involvement
CONCLUSION: The present study shows no differences in the expression of EMT markers between node positive and node negative vulvar cancers. The evaluation of immunostaining within the micro-anatomical context indicates that an EMT-phenotype is restricted to the tumor cells at the front of invasion. Paired analyses of vulvar carcinomas and their lymph node deposits suggest mesenchymal-epithelial transition (MET) in the metastatic deposits. Immunohistochemical staining results may suggest that EMT is more prevalent in vulvar cancer with aberrant p53 staining.PMID:34495397 | DOI:10.1007/s00432-021-03715-2 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 8, 2021 Category: Cancer & Oncology Authors: Christine E Brambs Lars-Christian Horn Meinhard Mende Michael H öckel Christine Eckey Gesine Grit Ruth Hiller Anne Kathrin H öhn Source Type: research

Psoralidin exerts anti-tumor, anti-angiogenic, and immunostimulatory activities in 4T1 tumor-bearing balb/c mice
CONCLUSIONS: Psoralidin shows the anti-cancer potential in an animal model of breast cancer; however, further studies are recommended to elucidate its mechanisms of action.PMID:34496167 | DOI:10.1515/hmbci-2021-0028 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 8, 2021 Category: Cancer & Oncology Authors: Davar Amani Elham Shakiba Ehsan Motaghi Hiva Alipanah Mahshad Jalalpourroodsari Mohsen Rashidi Source Type: research